Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends, Size, Share, Industry Share, Grow
2 New Study Examines Role of Anti-VEGF Injections on Treatment Patterns
3 VIDEO: Interaction between VEGF, Tie, integrin pathways plays a role in retinal disease
4 Anti-VEGF Injections Increases the Risk of Open-Angle Glaucoma
5 The Expression of VEGF and CD31 in Endometrial Lesions and Its Associa | CMAR
6 Gene Mutations and Transcriptional Signatures Correlate With Response to Therapy in Advanced Renal Cell Carcinoma
7 Fewer anti-VEGF injections needed after treatment with ADVM-022 in wet AMD
8 Choroidal thickness decreases after five anti-VEGF injections
9 Tag: VEGF/VEGFR Inhibitor DrugsItaly
10 (AAO) Considerations when using anti-VEGF for treating AMD
11 Race Impacts DME Treatment Efficacy, Study Finds
12 Teleretinal screening: Effective, less costly option for DR
13 Anti-VEGFs may be used to treat retinal arterial macroaneurysms
14 Anti-VEGF therapy did not prevent conversion to neovascular AMD in fellow eyes
15 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size, Key Manufacturers, Demand, Application And Opportunities By 2027
16 Pitt Scientists Find Clues, Possible Treatment for Vision Loss Caused by Herpes Virus Infection
17 Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 AAO
18 An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma ...
19 Beovu offers model on how to handle unexpected complications
20 Real-World Outcomes in Patients with Diabetic Macular Edema Treated Lo | OPTH
21 FDA Accepts Review of Samsung Bioepis and Biogen’s Ranibizumab Biosimilar
22 Aflibercept Benefits Macular Edema Visual Acuity at 2 Years
23 Investigational Drug Shows Promise Treating Wet AMD
24 PRN Injections Yields Improvements for Diabetic Retinopathy Patients
25 Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
26 Fluocinolone Implant Real-World Experience Matches DME Trials
27 Exploring Treatments in Patients With Favorable-Risk RCC
28 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026
29 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market 2020 Booming Strategies of Top Companies – Roche, TRACON Pharmaceuticals, Santen Oy, Regeneron Pharmaceuticals
30 Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
31 World’s Largest Specialty Clinical Data Registry Reveals Insights into Eye Disease Prevention and Treatment
32 Have you restarted performing comprehensive eye exams at each injection visit?
33 The SARS-CoV-2 Spike Protein Interferes With Pain Perception, But Does It Help Transmission?
34 Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
35 A bypass route for the coronary vessels in the heart?
36 Age-related macular degeneration: Early detection and timely treatment may help preserve vision
37 High Rates of nAMD Patients Cease Anti-VEGF Treatment Over Time
38 Scripps Research study says new strategy for treating retinal diseases shows promise
39 Retina specialists receptive but cautious regarding use of Beovu
40 VEGF Antibody Market Technological Trends in 2020-2026| Leading Players like Thermo Fisher, MilliporeSigma, Santa Cruz Biotechnology, Abcam, etc
41 Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
42 Australia's Opthea lists on Nasdaq in $128M IPO, gears up for phase III wet AMD trials
43 Outlook Therapeutics: Not That Bright An Outlook
44 Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth
45 Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity in Metastatic ccRCC
46 VEGF Targeted Drugs for Breast Cancer Market Growth Rate, Demands, Status And Application Forecast To 2027
47 Surge in PD-1/PD-L1 targeted combination trials is shaping future of cancer treatment
48 Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: An analysis of the IRIS Registry
49 Anti-VEGF Injections Associated with Cognitive Impairment in AMD Patients
50 Researchers Estimate Lifetime Outcomes of Anti-VEGF Treatment for nAMD
51 Macular Degeneration Treatment Market: Brands with drug patents accused of extortionately pricing high demand products
52 Cabozantinib Leading the Emerging Therapies in Advanced RCC
53 Exploring four decades of change in retina
54 ANZUP Mini ASM 2020: Renal Cell Carcinoma
55 BLOG: How the FDA system can fail
56 Fast Five Quiz: Exudative AMD Management
57 When good retinal surgery makes glaucoma go bad
58 Comparison of VEGF‐A Values between Pregnant Women with COVID‐19 and Healthy Pregnancies and Its Association with Composite Adverse Outcomes
59 VEGF Inhibitor Drugs Market Size 2020
60 Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma at ESMO ASIA Virtual Congress 2020
61 Repurposing Heart Drugs Could Improve Responses to PDL1 Immunotherapy in Cancer Patients
62 VA less improved in Black patients with DME after anti-VEGF treatment
63 VEGF Targeted Drugs for Breast Cancer Market Size, Revenue, Gross Margin, Sales, Scope, And Growth Rate Analysis 2020-2027
64 Older patients with melanoma may have poorer response to anti-VEGF therapy
65 Novel Anti-VEGF Delivery System Aims to Reshape AMD Treatment
66 St18 is a negative regulator of VEGF
67 Dexamethasone for Macular Edema Unresponsive to Anti-VEGF
68 Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database
69 Global VEGF/VEGFR Inhibitor Drugs Market 2020 Scope of Current and Future Industry, SWOT Analysis and Investment Feasibility 2025
70 SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity
71 Could New Therapies for Macular Degeneration Leave Anti-VEGF Biosimilars Behind?
72 Anti-VEGF Therapy May Not Improve Outcomes in Diabetic Macular Edema
73 Global Diabetic Retinopathy Market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis 2020-2026
74 Anti-VEGF Therapy for Diabetic Retinopathy Gets to the Root Cause
75 Strategies for sustained anti-VEGF delivery aimed at consistent dosing, durability
76 Targeted Drug VEGF Inhibitors for NSCLC Market Size, Revenue, Share, Scope, Growth Rate And Forecast To 2027
77 Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology
78 Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid Cancer
79 3 Clinical Trial Setbacks: Ovid, Histogen and Minerva
80 Puzzling PRP possibilities and dermatology
81 Extended anti-VEGF treatment may depend more on patient than dose, administration
82 Outlook Therapeutics Announces Creation of Global Retina Advisory Council
83 More frequent anti-VEGF injections in AMD linked to increased cognitive impairment risk
84 Epac1 inhibition ameliorates pathological angiogenesis through coordinated activation of Notch and suppression of VEGF signaling
85 Combination therapy might improve outcomes in treatment-resistant liver cancer
86 What is the Role of Vascular Endothelial Growth Factor?
87 Anti-VEGF therapy may aid visual acuity in some nAMD patients
88 Network meta-analysis finds little difference among anti-VEGF regimens for wet AMD
89 2020 Cancer update: New drugs and developments
90 Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
91 Lifetime Outcomes of Anti-VEGF Treatment in Neovascular AMD
92 Helping patients who do not respond to anti-VEGF therapy
93 Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Fol | OPTH
94 Emphysema Preclinical Study Shows PR1P Reduces Lung Cell Death
95 Trial shows faricimab blocks ANG-2, VEGF-A
96 Response to adjuvant bevacizumab among patients with resected melanoma may vary by age
97 Saving memories: Do anti-VEGF agents contribute to cognitive loss?
98 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden
99 Eluminex Biosciences Closes $50M Series A Financing
100 Using Current Anti-VEGF Agents to Lessen the Injection Burden and Improve Adherence and Visual Outcomes